Inovio Pharmaceuticals, Inc. INO suffered a wider net loss for the second quarter. However, its revenue not only increased year-over-year, but also came in above the estimate, sending the stock higher in Monday's pre-market trading.
The company reported a net loss of $18.7 million (or a loss per share of $0.26) in the second quarter. In comparison, it incurred a loss of $6.25 million or a loss per share of $0.06 in the year-ago period. Street expected a loss of $0.21 a share.
Inovio's total revenue was $6.2 million versus $5.3 million recorded in the previous year's quarter. Analysts projected $4.95 million revenue.
The company attributed the increase in revenue to an increase in development payments from its DARPA Ebola grant.
Following this, the stock traded $0.14 up, or 1.42 percent, to $9.99 in the pre-market trading on Monday; however, at time of publication, Inovio was trading down 3.15 percent on the day at $9.54.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
